Dymon Asia Capital Singapore PTE. LTD. Makes New $1.86 Million Investment in BioNTech SE Sponsored ADR $BNTX

Dymon Asia Capital Singapore PTE. LTD. purchased a new stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 17,500 shares of the company’s stock, valued at approximately $1,863,000. BioNTech accounts for 0.3% of Dymon Asia Capital Singapore PTE. LTD.’s investment portfolio, making the stock its 20th biggest position.

Other hedge funds and other institutional investors have also made changes to their positions in the company. LRI Investments LLC increased its holdings in BioNTech by 234.6% in the second quarter. LRI Investments LLC now owns 445 shares of the company’s stock valued at $47,000 after purchasing an additional 312 shares during the last quarter. Hantz Financial Services Inc. grew its position in shares of BioNTech by 472.0% during the 2nd quarter. Hantz Financial Services Inc. now owns 572 shares of the company’s stock worth $61,000 after buying an additional 472 shares during the period. Banque Transatlantique SA bought a new stake in shares of BioNTech in the 1st quarter valued at about $80,000. Allworth Financial LP increased its stake in shares of BioNTech by 1,176.8% in the 2nd quarter. Allworth Financial LP now owns 1,213 shares of the company’s stock valued at $129,000 after acquiring an additional 1,118 shares during the last quarter. Finally, NewEdge Advisors LLC acquired a new stake in shares of BioNTech in the 1st quarter valued at approximately $167,000. 15.52% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

BNTX has been the topic of several analyst reports. Cowen reiterated a “hold” rating on shares of BioNTech in a report on Monday, November 3rd. Bank of America dropped their price objective on BioNTech from $134.00 to $130.00 and set a “buy” rating on the stock in a research note on Wednesday, October 22nd. HC Wainwright lifted their target price on BioNTech from $136.00 to $140.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a report on Tuesday, October 14th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $151.00 price target on shares of BioNTech in a research report on Wednesday, December 3rd. Ten equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, BioNTech presently has a consensus rating of “Moderate Buy” and an average price target of $136.42.

BioNTech Stock Performance

BNTX opened at $95.85 on Wednesday. The business’s 50-day simple moving average is $102.78 and its 200 day simple moving average is $105.15. BioNTech SE Sponsored ADR has a 52-week low of $81.20 and a 52-week high of $129.27. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.02 and a current ratio of 7.12. The firm has a market capitalization of $21.58 billion, a PE ratio of -36.44 and a beta of 1.30.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of $0.75 by ($0.89). BioNTech had a negative net margin of 17.91% and a negative return on equity of 3.03%. The firm had revenue of $1.78 billion during the quarter, compared to analyst estimates of $1.21 billion. During the same quarter in the prior year, the business earned $0.81 EPS. The business’s revenue was up 22.0% compared to the same quarter last year. As a group, sell-side analysts expect that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current fiscal year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.